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ABSTRACT
The BCCIP (BRCA2- and CDKN1A-interacting protein) is
an important cofactor for BRCA2 in tumor suppression.
Although the low expression of BCCIP is observed in
multiple clinically diagnosed primary tumor tissues
such as ovarian cancer, renal cell carcinoma and col-
orectal carcinoma, the mechanism of how BCCIP is
regulated in cells is still unclear. The human INO80/YY1
chromatin remodeling complex composed of 15 sub-
units catalyzes ATP-dependent sliding of nucleosomes
along DNA. Here, we ﬁrst report that BCCIP is a novel
target gene of the INO80/YY1 complex by presenting a
series of experimental evidence. Gene expression
studies combined with siRNA knockdown data locked
candidate genes including BCCIP of the INO80/YY1
complex. Silencing or over-expressing the subunits of
the INO80/YY1 complex regulates the expression level of
BCCIP both in mRNA and proteins in cells. Also, the
functions of INO80/YY1 complex in regulating the
transactivation of BCCIP were conﬁrmed by luciferase
reporter assays. Chromatin immunoprecipitation (ChIP)
experiments clarify the enrichment of INO80 and YY1 at
+0.17 kb downstream of the BCCIP transcriptional start
site. However, this enrichment is signiﬁcantly inhibited
by either knocking down INO80 or YY1, suggesting the
existence of both INO80 and YY1 is required for
recruiting the INO80/YY1 complex to BCCIP promoter
region. Our ﬁndings strongly indicate that BCCIP is a
potential target gene of the INO80/YY1 complex.
KEYWORDS BCCIP, human INO80, chromatin
remodeling complex
INTRODUCTION
The BRCA2- and CDKN1A (Cip1, p21)-interacting protein
BCCIP is alternatively spliced α and β isoforms (Liu et al.
2001; Ono et al. 2000). Both isoforms share N-terminal
acidic domain (NAD, include 258 amino acids) and the
internal conserved domain (ICD) (Liu et al. 2001). As an
important cofactor for BRCA2 in tumor suppression,
BCCIP has been implicated in many important cellular
processes with obvious links to cancer. Knocking down
BCCIP with siRNA in cells leads to defective DNA damage
repair (Lu et al. 2005), abnormal cell cycle (Meng et al.
2004; Meng et al. 2004) and genomic instability (Meng
et al. 2007). Recently, other colleagues and we have
reported that BCCIP was down-regulated in several can-
cer tissues such as renal cell carcinoma, ovarian cancer
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and colorectal carcinoma (Meng et al. 2003; Liu et al.
2013). Thus, it is important to clarify the role of BCCIP in
tumorigenesis, especially to know how the BCCIP is reg-
ulated in cells.
Yin Yang 1 (YY1), a member of the GLI-Krüppel class
proteins, was ﬁrst discovered as a DNA binding protein (Shi
et al. 1991; Seto et al. 1991; Park and Atchison 1991; Har-
iharan et al. 1991). It is a ubiquitously expressed and evo-
lutionarily conserved protein in human cells. Domain
research found that YY1 includes not only an activation
domain, but also contains a repression domain (Thomas and
Seto 1999; Shi et al. 1997). In subsequent studies, YY1 has
been clariﬁed as a versatile protein which can either repress
or activate gene transcription by recruiting different cofactors
such as histone deacetylases (HDACs), methyltransferase
enhancer of zeste homolog 2 (Ezh2), CREB-binding protein
(CBP), and P300/CBP-associated factor (PCAF) (Yao et al.
2001; Lee et al. 1995).
Using biochemical puriﬁcation approaches, we previously
veriﬁed that YY1 is tightly associated with the human INO80
(INO80) chromatin remodeling complex (Jin et al. 2005). All
evolutionarily conserved subunits (include actin-related pro-
teins Arp4, Arp5, Arp8, Tip49a and Tip49b AAA+ ATPases,
and hIes2 and hIes6) assembled on the conserved helicase-
SANT-associated/post-HSA (HSA/PTH) and ATPase
domains of INO80 protein (Jin et al. 2005). Both HSA/PTH
and ATPase domains in INO80 protein are essential for
catalyzing the ATP-dependent nucleosome remodeling
activity of the INO80 complex. Based on YY1 with Arp4 and
Arp8 together participate in assembling helicase-SANT-as-
sociated/post-HSA (HSA/PTH) module, suggesting that like
other conserved subunits, YY1 is also essential for main-
taining the ATP-dependent nucleosome remodeling activity
of the INO80 complex (Chen et al. 2011). Experimental
evidence indicates that yeast Ino80 is required for proper
transcriptional regulation of many target genes (Morrison
and Shen 2009), while in Drosophila, INO80 facilitates
transcriptional repression of ecdysone-regulated genes
during prepupal development (Neuman et al. 2014). Recent
experimental results demonstrate that INO80 is also required
in ESC self-renewal, somatic cell reprogramming, and
blastocyst development (Wang et al. 2014). Although gen-
ome-wide studies show that INO80 binds many, but not all,
loci in the genome (Moshkin et al. 2012), it is unclear whe-
ther there is a direct correlation between INO80 binding and
target gene expression levels. One possibility is that YY1 as
a transcription factor helps INO80 complex to recognize
INO80-target genes and recruits the complex to some target
genes such as CDC6 and GRP78 (Cai et al. 2007). In this
study, using molecular and cell biology approaches, we ﬁrst
show that the BCCIP might be a novel target gene of the
INO80 /YY1 chromatin remodeling complex. Our results will
provide a strong theoretical basis to elucidate the BCCIP
functions in cells.
RESULTS
BCCIP was selected as a candidate target gene
of the INO80/YY1 complex from gene expression
proﬁles
Human INO80 complex is one of the most highly conserved
chromatin remodelers. Eight core subunits (Arp5, Arp8,
TIP49a/b, Ies2, Ies6, Arp4, and YY1) are evolutionary con-
served and form an enzyme core including HSA and SNF2
modules. Except for conserved subunits, INO80 complex
contains 6 metazoan-speciﬁc subunits which all assemble on
N-terminus of INO80 protein and form an N-terminal regula-
tory module (Jin et al. 2005; Chen et al. 2011) (Fig. 1A).
Increasing evidence suggests the functions of INO80/YY1
complex in gene transcriptional regulation (Morrison and
Shen 2009; Conaway and Conaway 2009), but the precise
mechanisms are still unclear. To investigate the target genes
of the INO80/YY1 complex, total RNA from HeLa cells with
speciﬁc siRNA (siINO80, siArp8, Arp5, siIes2 and siIes6)
knocked down (Fig. 1B) were sent to EMTD Science and
Technology Development Co., Ltd. (Beijing, China) for DNA
microarray. As shown in Fig. 1C, a total of 1932, 1445, 1235,
2707 and 2159 genes were differentially expressed among
INO80, Arp8, Arp5, hIes6 or hIes2 and NTsiRNA knockdown
HeLa cells, respectively. Hundreds of overlapping genes are
found to be regulated by INO80, Arp8, Arp5, hIes6 and hIes2,
which are components of the HSA and SNF2 module. On the
other hand, a total of 602 genes were co-regulated by INO80
and Arp8 which participate in assembling HSA module (data
not shown). Selected overlapping co-regulated genes (8
down and 6 up) in INO80/YY1 complex knockdown HeLa
cells are shown in Table 1. mRNA from INO80- and Arp8-
siRNA knockdown cells (Fig. 1E) was measured with RT-
qPCR (Fig. 1F). Compared to NT siRNA control, selected
gene mRNA including BCCIP, TNFRSF21, and BRMS1L was
down-regulated with siRNA knockdown of INO80 and Arp8 in
HeLa cells. In contrast, RAF1 and PTTG1IP mRNAs was up-
regulated. However, there was no change of mRNA of
RAB24, RAB22A, and ST7L. Table 2 compared the results of
microarray illumina and RT-qPCR. In addition, differentially
expressed genes (DEGs) in INO80/YY1 complex knocked
down cells were used for KEGG annotation by using DAVID
web annotation tool. DEG-enriched pathways in INO80
complex knockdown cells were shown previously (Chen et al.
2011). Fig. 1D shows the differentially regulated microarray
genes in cancer pathway after knocking down the indicated
subunits of INO80/YY1 complex.
The expression of BCCIP was regulated by INO80/YY1
complex in HeLa and 293T cells
UCSC (The University of California-Santa Cruz) Genome
Browser at http://genome.ucsc.edu provides timely, conve-
nient access to a database of high-quality genome sequence
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and annotation (Karolchik et al. 2013). Based on UCSC
database (ChIP-Seq) search, we found that YY1 was re-
stricted to the BCCIP transcriptional start site proximal region
in different types of cell lines including human lung carci-
noma type II epithelium-like A549, human liver hepatocellu-
lar carcinoma HepG2 and human colon cancer HCT116. To
clarify this observation, we ﬁrst examined the BCCIP
expression level in YY1-siRNA knockdown HeLa cells. As
shown in Fig. 2A, dose-dependent down-regulation of
BCCIP (lower panel) in YY1-siRNA knockdown (upper
panel) HeLa cells was conﬁrmed by qPCR. Furthermore, low
protein levels of BCCIP in YY1-siRNA knockdown HeLa
cells were also detected by western blot (Fig. 2B) and
immunoﬂuorescence staining (Fig. 2C) approaches,
respectively. Given that YY1 is a subunit of the INO80
chromatin remodeling complex, the implication of INO80
complex in regulating BCCIP is speculated. To determine
whether BCCIP is a potential target gene of the INO80/YY1
complex, we evaluated the BCCIP expression level in
INO80- and Arp8- (evolutionary conserved subunit of the
INO80 complex) siRNA knockdown HeLa cells. Declined
protein levels of BCCIP by knocking down INO80 and Arp8
in HeLa cells were presented by western blot (Fig. 2E and
2F) and immunoﬂuorescence staining (Fig. 2D), suggesting
the involvement of INO80/YY1 complex in regulating the
BCCIP expression.
Differentially regulated





















































































































































Figure 1. BCCIP is found in overlapping expressed gene proﬁles in INO80/YY1 complex-knockdown HeLa cells.
(A) Functional domains of INO80/YY1 complex. NTD, N-terminal domain; HSA, helicase-SANT-associated domain; SNF2_N,
SNF2 family N-terminal domain; Ins, insertion domain; HELICc, Helicase C-terminal domain; CTD, C-terminal domain. (B) Relative
mRNA levels in siINO80, siArp8, siArp5, siIes2, and siIes6 knockdown HeLa cells. (C) Gene expression proﬁles in speciﬁc-siRNA
knockdown Hela cells. Stacked column chart represents the total number of regulated genes in indicated speciﬁc siRNA knockdown
HeLa cells. Each bar in the stacked column chart is composed of down- and up-regulated genes. (D) Differentially regulated
microarray genes in cancer pathway in INO80/YY1 complex knockdown HeLa cells. (E) Knockdown efﬁciency. HeLa cells were
transfected with 15 pmol INO80- or hArp8-siRNA and siNT (as control). (F) Veriﬁcation of the mRNA of select genes from gene
expression proﬁles. 48 h after siRNA transfection, RT-qPCR was performed to assess the relative mRNA levlel (n = 3). Bar graphs
show ratios of RT-qPCR signals to GAPDH (all signals normalized to siNT). **P < 0.01 in comparison with siNT control (Student t-
test).
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Human INO80 facilitates the transactivation of BCCIP
To further explore whether the INO80/YY1 chromatin
remodeling complex affects the transactivation of BCCIP,
three designed BCCIP promoter region was sub-cloned into
pGL4 luciferase vector (Fig. 3A). Constructed pGL4-BCCIP-
Luc plasmids containing different BCCIP promoter region
were ﬁrst tested in dual luciferase assay (Fig. 3B). Then, the
impact of INO80 on BCCIP transactivation was estimated by
co-transfection of pGL4-BCCIP-Luc with Flag-INO80 plas-
mids. As shown in Fig. 3C, in contrast to a basal-level luci-
ferase activity, co-transfection of pGL4-BCCIP-Luc and
INO80 dose-dependently increased BCCIP-luciferase activ-
ity in all cases, indicating the roles of INO80 complex in
regulating the transactivation of BCCIP.
Chromatin remodeling activity of the INO80 complex
might be associated with regulation of BCCIP
expression
To investigate the effects of INO80 complex on BCCIP-me-
diated transactivation, pGL4-BCCIP-Luc vector containing
391 bp promoter region (−330 ∼+61 bp) was used in sub-
sequent experiments. As shown in Fig. 4A, co-transfection of
pGL4-BCCIP-Luc vector with Flag-tagged INO80, Arp5, and
Arp8 increased not only luciferase activities (data not shown)
but also intracellular BCCIP proteins in a dose-dependent
manner. Compared to pcDNA3.1 control group, statistically
signiﬁcant differences were found in INO80 (P < 0.01 at 0.2,
0.4, and 0.8 μg of plasmids, respectively), Arp5 (P < 0.05 at
0.8 μg of plasmids), or Arp8 (P < 0.01 at 0.4 and 0.8 μg of
Table 1. Select overlapping co-regulated genes in INO80/YY1 knockdown gene expression proﬁles
Gene symbol Gene ID Gene description Up or Down Fold change
AMHR2 NM_020547 Anti-mullerian hormone receptor, type II Down −3.58
BCCIP NM_016567 BRCA2 and CDKN1A interacting protein Down −3.62
CDH1 NM_0043609 Cadherin 1, type 1 Down −4.97
CCL28 NM_019846 Chemokine (C-C motif) ligand 28 Down −2.61
FGFBP1 NM_005130 Fibroblast growth factor binding protein1 Down −3.65
GRTP1 NM_024719 Growth hormone regulated TBC protein 1 Down −3.21
TPD52 NM_001025252 Tumor protein D52 Down −2.35
WTIP NM_059037 Wilms tumor1 interacting protein Down −3.15
CDKN1A (p21) NM_078467 Cyclin-dependent kinase inhibitor 1A Up 6.92
EGFR NM_005228 Epidermal growth factor receptor Up 9.5
GAS1 NM_002048 Growth arrest-specifc 1 Up 4.0
MBD1 NM_015845 Methy-CpG binding domain protein 1 Up 5.26
RAF1 NM_002880 v-raf1 murine leukemia viral oncogene homolog1 Up 4.41
TGFBR1 NM_004612 Transforming growth factor, beta receptor 1 Up 4.56
Genes shown in table are the selected overlapping expressed genes in at least three subunits of INO80/YY1 complex knockdown HeLa cells.
Table 2. Comparison of the results of the microarray-illumina and qPCR
Gene symbol Gene ID siINO80 siArp8
Illumina qPCR Illumina qPCR
BCCIP NM_016567 Down Down Down Down
TNFRSF21 NM_014452 Down Down Down –
BRMS1L NM_032352 Down Down Down Down
RAF1 NM_002880 Up – Up Up
RAB24 NM_001031677 Up – Up –
RAB22A NM_020673 Down – Down –
ST7L NM_138729 Up – Up –
PTTF1IP NM_004339 Up Up Up Up
Co-regulated genes selected from different speciﬁc subunit of the INO80/YY1 complex knockdown gene expression proﬁles are tested by
quantitative PCR (qPCR). The performed qPCR results were then compared with DNA microarray illumine data.
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plasmids, respectively) transfected 293T cells (Fig. 4B),
suggesting the importance of enzyme core including HSA
and SNF2 modules of the INO80 complex in regulating
BCCIP expression. To further conﬁrm this result, point or
delete mutations of INO80 protein were designed (Fig. 4C).
BCCIP protein levels in overexpressed INO80wt, INO80mt,
INO80 N-HSA, and INO80CTD proteins in 293T cells were
analyzed by western blot with anti-BCCIP antibody. Con-
sistent with previous results, increased tendency of both
BCCIPα and BCCIPβ was detected in INO80wt over-ex-
pressed 293T cells (Fig. 4D, left panel). However, this phe-
nomenon is reversed by over-expression of INO80mt
(E653Q, a DEAD/H box point mutation) which interfere with
INO80 ATPase activity. As a result, BCCIP proteins are
gradually decreased by increasing the transfection amount
of INO80mt (Fig. 4D, second panel from the left), demon-
strating the importance of ATPase activity of the INO80
complex in BCCIP expression. In addition, except for
BCCIPα at 0.8 μg transfection of INO80 N-HSA (P < 0.05),
little changes of BCCIP proteins were observed in INO80 N-
HSA transfected 293T cells (Fig. 4D, third panel from the
left). Furthermore, co-transfection of pGL4-BCCIP-Luc vec-
tor with INO80CTD, decreasing tendency of both BCCIPα
and BCCIPβ was represented in a dose dependent manner,
and the statistically signiﬁcant differences were obtained at
0.8 μg transfection of INO80CTD (Fig. 4D, right panel).
Above experimental results indicate that enzymatic activities
of the INO80 complex might be associated with the regula-
tion of BCCIP expression. Quantiﬁed proteins of BCCIPα


































































































Figure 2. The INO80/YY1 chromatin remodeling complex is implicated in regulating BCCIP expression in HeLa cells.
(A) Down regulation of BCCIP mRNA in siYY1 knockdown HeLa cells. Relative mRNA levels of YY1 and BCCIP were measured by
RT-qPCR. Each bar represents the mean of 3 independent experiments. **P < 0.01 in comparison with siNT-transfected control
(Student t-test). (B) Reduction of BCCIP protein levels by knocking-down YY1 in HeLa cells. Whole cell lysate from siYY1 knockdown
cells was analyzed by western blot. Speciﬁc proteins were detected by indicated antibodies (GAPDH as internal control). Anti-BCCIP
antibody recognizes both α- and β- isoform of BCCIP. (C and D) Immunoﬂuorescence stained BCCIP proteins. HeLa cells were
transfected with YY1-, INO80-, and Arp8 siRNA. 48 h later, immunoﬂuorescence staining was carried out using BCCIP antibody.
DAPI staining shows total nuclei. (E) Western blot analysis of BCCIP proteins in INO80 (upper) and Arp8 (down) knocked down HeLa
cells. Prepared whole cell lysate from INO80- or Arp8- siRNA knocked down HeLa cells were analyzed by western blot. Quantiﬁed
protein levels were shown in (F). **p < 0.01 in comparison with siNT-transfected control (Student t-test).
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INO80/YY1 chromatin remodeling complex is restricted
to the BCCIP transcriptional start site proximal region
Data in the previous experiment clearly show that BCCIP
level in both mRNA and protein, and the transactivation of
BCCIP in cells is regulated by INO80/YY1 chromatin
remodeling complex. To further determine whether the
BCCIP is transcriptionally controlled by INO80/YY1 complex,
indicated primer sets were designed to amplify ChIP DNA
(Fig. 5A, upper panel). Ampliﬁed ChIP DNA by each speciﬁc
primer set for BCCIP promoter proximal region as well as the
region far away from the transcriptional start site was con-
ﬁrmed by qPCR, and visualized in 2.5% DNA agarose with
Ethidium bromide (Fig. 5A, lower panel). Human INO80 and
YY1 speciﬁc antibodies were then used in ChIP assays. As
shown in Fig. 5B, both INO80 (upper) and YY1 (lower) are
recruited at +0.17 kb downstream of the BCCIP transcrip-
tional start site, indicating the co-localization of INO80 and
YY1 on the BCCIP promoter region. Further analysis of
performed qPCR products on 2.5% DNA agarose gel
acquired a signiﬁcant enrichment both in INO80 and YY1
ChIP at +0.17 kb downstream of the BCCIP transcriptional
start site (Fig. 5C). However, knockdown INO80 by trans-
fecting pBS-shINO80 (Fig. 6A) in 293T cells signiﬁcantly
blocked the recruitment of INO80 and YY1 at the +0.17 kb
downstream of the BCCIP transcriptional start site (P < 0.01
in both cases), conﬁrming the binding of INO80/YY1 com-
plex at BCCIP promoter region (Fig. 6B). Similarly, silencing
YY1 by siRNA (Fig. 6C) in 293T cells inhibited the recruit-
ment of INO80 at the +0.17 kb downstream of the BCCIP
transcriptional start site (P < 0.01), but not at +2.8 bp far
away from the downstream of the BCCIP transcriptional start
site, suggesting the requirement of YY1 for binding of INO80
to BCCIP promoter region (Fig. 6D).
DISCUSSION
It has been known that the INO80 complex is highly con-
served from yeast to human. Evolutionarily conserved sub-
units including YY1 form an enzyme core which is composed
of two modules (HSA and SNF2) assembled on the con-
served HSA/PTH and ATPase domains of the INO80 protein
(Fig. 1A). Although the precise functions of those two mod-
ules remain to be explored, actin-related protein Arp4 and
Arp8 have been reported to bind to DNA and histones,
suggesting the contributions of the INO80 complex in
recognition of DNA and/or nucleosome substrates (Seeber
et al. 2013; Shen et al. 2003). On the other hand, recognition
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Figure 3. Transactivation of BCCIP is facilitated by INO80/YY1 chromatin remodeling complex. (A) Schematic of construction
of pGL4-BCCIP-Luc plasmids. A length of 926 bp (−724 ∼+202 bp), 391 bp (−330 ∼+61 bp), and 272 bp (−277 ∼ −5 bp) region of
BCCIP promoter was introduced into pGL4-Luc vector. The luciferase activity of each plasmid was shown in B. (C) A dual luciferase
assay. pGL4-BCCIP-Luc vectors and INO80wt plasmid (0.2, 0.4 and 0.8 μg) were co-transfected into 293Tcells. 48 h later, luciferase
activity in the lysates was determined by a dual luciferase assay. Error bars represent data from three independent experiments.
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beneﬁcial to the ATP-dependent nucleosome remodeling
activity, thereby regulating gene expression through chro-
matin structure alteration. Based on the analysis of per-
formed gene expression proﬁles from INO80-, Arp8-, Arp5-,
hIes6- and hIes2-knockdown HeLa cells, we not only clari-
ﬁed that over thousands of genes were regulated in each
gene expression proﬁle, but also found that hundreds of
genes were co-regulated by silencing the subunits which
composed of SNF2 (Arp5, Ies6 and Ies2) and HSA (Arp8)
modules (Cao et al. 2015). Also, enrichment of differentially
expressed genes in multi-KEGG pathways including
pathways in cancer was conﬁrmed by KEGG pathway
enrichment analysis, indicating the importance of the INO80
complex in cellular biological processes such as cancer
pathway (Fig. 1D) (Chen et al. 2011).
We previously reported that zinc-ﬁnger transcription factor
YY1 is tightly associated with human INO80 chromatin
remodeling complex, and with actin-related proteins (Arp4
and Arp8) together, YY1 assembles HSA module on the
HSA/PTH domain of INO80 protein, demonstrating the roles
of YY1 in maintaining the nucleosome remodeling activity of
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Figure 4. Chromatin remodeling activity of the INO80/YY1 complex might be important for regulating the BCCIP expression.
(A) Facilitation of BCCIP expression by INO80/YY1 complex. 293T cells were co-transfected with pGL4-BCCIP (contains 391 bp
promoter region) -Luc vector and Flag tagged INO80, Arp5, and Arp8 pcDNA plasmids (0.2, 0.4 and 0.8 μg). 48 h later, Cells were
harvested and whole cell lysate was prepared. BCCIP proteins were checked by western blot with anti-BCCIP antibody which can
recognize both BCCIPα and BCCIPβ. Here shows representative ﬁgures of western blot analysis. (B) Quantiﬁed proteins. Western
blot images from (A) experiments were quantiﬁed with densitometry using Quantity One Basic software (BioRad). Bar graph shows
the standard error of the mean of three independent experiments. *P < 0.05, *P < 0.01 in comparison with pcDNA3.1-vector
transfected control (Student t-test). (C) Point or delete mutation of INO80. (D) Effect of INO80 protein on BCCIP expression. pGL4-
BCCIP-Luc (contains 391 bp promoter region)vector was co-transfected with Flag tagged INO80wt, INO80mt (E653Q), INO80 N-
HSA, and INO80CTD pcDNA plasmids (0.2, 0.4 and 0.8 μg) into 293Tcells. Prepared whole cell lysate was subjected to western blot
analysis. (E) Quantiﬁed proteins. Western blot images from (D) three independent experiments were scanned and quantiﬁed with
densitometry using Quantity One Basic software (BioRad). *P < 0.05, *P < 0.01 in comparison with pcDNA3.1-vector transfected
control (Student t-test).
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More importantly, as an essential co-activator, YY1 can
recruit the INO80 complex to some target genes such as
CDC6 and GRP78 (Cai et al. 2007). Based on our gene
expression proﬁles and screening experiments, BCCIP was
chosen as one of the potential candidates of target genes of
the INO80 complex. Based on database search in UCSC
Genome Browser, we found that YY1 is restricted at the
BCCIP transcriptional start site proximal region in different
types of cancer cell lines including A549, HepG2 and
HCT116, suggesting the functions of YY1 or INO80/YY1
complex in regulating the expression of BCCIP.
In this report, we ﬁrst veriﬁed that BCCIP is a novel target
gene of the INO80 chromatin remodeling complex by pre-
senting a series of experimental evidence. The levels of
BCCIP both in mRNA and protein were not only regulated by
silencing- or over-expressing- YY1 (Fig. 2), but also were
changed by knocking down INO80 and Arp8 or over-ex-
pression of INO80, Arp5, and Arp8 HeLa cells (Figs. 2 and
4A), suggesting the roles of INO80/YY1 complex, but not
limited to YY1, in regulating the BCCIP expression. ChIP
assays further veriﬁed that INO80 and YY1 co-localize the
BCCIP promoter region, and the binding site to BCCIP gene
was enriched at +0.17 kb downstream of the transcriptional
start site (Fig. 5). However, this enrichment was signiﬁcantly
inhibited in either INO80- or YY1- knocking down 293T cells
(Fig. 6), suggesting that (i) INO80/YY1 complex binds to the
BCCIP promoter region; (ii) binding of YY1 to the BCCIP
promoter region requires INO80; (iii) INO80 complex is
required for YY1 to gain access to target gene promoters
and to activate transcription of target genes.
In summary, we ﬁrst demonstrate that BCCIP might be a
novel target gene of the human INO80/YY1 chromatin
remodeling complex. This result will provide a theoretical
basis for further understanding and elucidating the functions
of BCCIP in tumorigenesis and cellular processes.
MATERIALS AND METHODS
Antibodies
Anti-BCCIP (16043-1-AP) antibody was obtained from Proteintech
Group (China, Wuhan). Anti-YY1 (sc-1703X) antibody, rabbit IgG
(sc-2027) and mouse IgG (sc-2025) were purchased from Santa































































































Figure 5. INO80 co-localize with YY1 at the BCCIP promoter. (A) Seven primer sets designed for amplifying ChIP DNA (upper
panel). PCR products from each primer set were conﬁrmed using 2.5% agarose gel (lower panel). (B) Co-occupying of INO80 and
YY1 at the BCCIP promoter region. ChIP assays were performed using INO80 (upper panel) or YY1 (lower panel) antibodies. ChIP
DNA was analyzed by qPCR. Bar graph shows the ratios of ChIP DNA signals (normalized to input) to IgG (also normalized to input).
Error bars represent the standard error of the mean of three independent experiments. (C) Enrichment of INO80/YY1 at the +0.17 kb
downstream of the BCCIP transcriptional start site. qPCR product at +0.17 kp downstream of BCCIP transcriptional start site was
visualized by ethidium bromide (upper panel) in 2.5% agarose gel. Quantiﬁed PCR signals (Quantity One software) were analyzed by
t-test (lower panel). Error bars indicate mean ± SE, and the signiﬁcant difference is expressed as **P < 0.01 (Student t-test).
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monoclonal antibody (F3165) were from Sigma (U.S.A.). Anti-INO80
(NM_017553, residue 1–526 aa), anti-Arp8 (NM_022899, full
length), and anti-GAPDH (NM_002046, full length) rabbit polyclonal
antibodies were raised against bacterially expressed proteins (Jilin
University).
Cell culture/maintenance
HEK293T (human embryonic kidney) and HeLa (human cervical
cancer) cells were grown on plates at 37 °C in DMEM (Dulbecco’s
modiﬁed Eagle’s Medium, GIBCO, Life TechnologiesTM, U.S.A.) with
10% fetal bovine serum (KangYuan Biology, China) and 1% Peni-
cillin-Streptomycin mixture (Thermo Fisher Scientiﬁc, U.S.A) in the
presence of 5% CO2.
Reverse transcription PCR (RT-PCR)
Total RNA was isolated using RNAiso Plus (Takara, Japan) and
reverse transcribed to cDNA using PrimeScript 1st Strand cDNA
Synthesis Kit (Takara, Japan). The resulting cDNA was analyzed by
quantitative real time PCR (qPCR) with EcoTM Real-Time PCR
System (Illumina, Gene Company Limited) (China, Hongkong). All
PCR products were synthesized using the following program: initial
denaturation step was conducted at 95 °C for 30 s, followed by 35
cycles of denaturation at 95 °C for 5 s, annealing at 60 °C for 30 s
and extension at 72 °C for 30 s. The following primer sets were used
for qPCR analysis: YY1, 5′-CCCTCATAAAGGCTGCACAA-3′ (for-
ward) and 5′-TGAACCAGTTGGTGTCGTTT-3′ (reverse), yielded a
147-bp product; Arp8, 5′-CCAGGCTGAGAAGGGTGATA-3′ (for-
ward) and 5′-GCAGGAAGAGTGTCTGTGGC-3′ (reverse), yielded a
200-bp product; BCCIP, 5′-TCAAGAGTTGGTTCTACGCTTC-3′
(forward) and 5′- CATGGGCAGAGCGATCTGT-3′ (reverse), yielded
a 111-bp product; INO80, 5′-CGGAATCGGCTTTTGCTA-3′ (forward)
and 5′-TGTCGGCTGGTCAGTTGG-3′ (reverse), yielded a 292-bp
product; and the internal control GAPDH, 5′-ATCACTGCCACCCA-
GAAGAC-3′ (forward) and 5′- ATGAGGTCCACCACCCTGTT-3′
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Figure 6. The INO80 chromatin remodeling complex may activate BCCIP gene through YY1. INO80- and YY1- ChIP in siINO80
knockdown 293Tcells were performed. INO80 knockdown efﬁciency was shown as A. ChIP DNA was analyzed by qPCR (B). Y-axis
shows the ratio of ChIP DNA signals to IgG. All ChIPs were normalized to input. Error bars represent mean ± SE (n = 3). * P < 0.05, **
P < 0.01 in comparison with pBS empty vector control (Student t-test). (C) Conﬁrmation of YY1 knockdown. (D) INO80 ChIP in YY1-
knockdown 293T cells. INO80 ChIP was carried out in YY1 knocked down 293T cells. +0.17 kb and +2.8 kb promoter primer sets
were used in ChIP experiments.
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cDNAs encoding the INO80 full length (NM_017553), INO80 point
mutation (E653Q), deletion mutations including INO80 N-HSA
(residue 1–521 aa), INO80CTD (residue 1223–1556 aa), Arp8
(NM_022899), Arp5 (BC038402), and YY1 (BC065366) proteins
were sub-cloned with Flag tags into pcDNA3.1(-). 293Tcells cultured
in 6-well tissue culture plates were transiently transfected with Flag-
tagged plasmids (1–2 μg) using PEI (Cat. 23966, Polysciences, U.S.
A.) according to the manufacturer’s recommendation. The ratio of
plasmids (μg) and PEI (μL) is 1:2. 48 h later, the whole cell lysate
was prepared and the proteins were isolated using SDS-PAGE gel
(10%). The speciﬁc proteins were detected by western blot with
speciﬁc antibodies.
siRNA/shRNA knockdown
HeLa cells were transfected with 10–20 pmol INO80- (D-004176),
YY1- (sc-36863), Arp8- (Customized) and non-targeting (NT)- siR-
NAs (D-001206, as control) for knocking down speciﬁc genes.
INO80-, Arp8- and non-targeting (NT)- siRNAs were ordered from
Dharmacon (U.S.A.). YY1 siRNAs were purchased from Santa Cruz
Biotechnology (U.S.A.). 48 h after transfection, total RNA or whole-
cell extract was prepared for RT-PCR and western blot analysis. In
ChIP assay, 293T cells were transfected with pBS-shINO80 plasmid
(10 μg/10 cm culture plate) or YY1 siRNAs for knocking down INO80
and YY1.
Luciferase reporter assay
BCCIP promoter region (926 bp, −724 ∼+202 bp; 391 bp,
−330 ∼+61 bp; 272 bp, −277 ∼ −5 bp) was introduced into pGL4-Luc
vector. Similar to previously described (Wu et al. 2013), 293T cells
grown on 12-well plates were co-transfected with 0.4 μg of pGL4
which encodes ﬁreﬂy luciferase, 0.12 ng of the control plasmid
Renilla luciferase vector which encodes renilla luciferase and
effector plasmid expressing pGL4-BCCIP using PEI reagent (Poly-
sciences, U.S.A.). Total effector plasmids in each transfection were
adjusted to 0.8 μg with empty vector. 48 h after transfection, the
transactivation activity of pGL4-BCCIP was determined by measur-
ing ﬁreﬂy and Renilla luciferase activities using the Dual-Luciferase
Reporter assay kit (Promega, U.S.A.).
Immunoﬂuorescence staining
∼30% conﬂuence HeLa cells in 24-well plates containing a cover-
slips (8D1007, Nest) on each well were transfected with INO80-,
Arp8- and YY1- siRNAs using RNAiMAX (Invitrogen). After 48 h,
cells were permeabilized with 0.3% TritonX-100 and incubated with
BCCIP antibody (1:200) at room temperature, then stained with
FITC-conjugated secondary antibody (rabbit/green: 1:300, sc-2012).
Cell nuclei were stained with DAPI containing Vectashield (Vector
Laboraries, Inc. H-1200). Fluorescence images were observed with
Olympus BX40F Microscope (Olympus Corporation).
Chromatin immunoprecipitation (ChIP) assays
1 × 107 of 293Tcells grown to 80% of conﬂuence were used for each
ChIP. INO80 and YY1 antibodies were used in ChIP assay. ChIP’d
DNA was subjected to qPCR. Each experiment was performed 2–3
independent times. Both speciﬁc antibody- and IgG-ChIP signal
were normalized to total input. The following primer sets were used
in qPCR: BCCIP −1.7 kb (−1769 ∼ −1603 bp), 5′-GACAGCTTCCTC
TCTTCTCCA-3′ (forward) and 5′-ATTTCGGTCTTTCCTGGGAGT-3′
(reverse); −1.2 kb (−1281 ∼ −1093 bp), 5′-CCCTCCACTCTTCTCTC
CAAA-3′ (forward) and 5′-CCCTCCACTCTTCTCTCCAAA-3′ (re-
verse); −0.8 kb (−860 ∼ −694 bp), 5′-CTCGAACTCCTGACCTCTGG
TG-3′ (forward) and 5′-CTGGAGCGCATTTCTTGACC-3′ (reverse);
−0.2 kb (−205 ∼ −53 bp), 5′-AGCTTTGGGAGGAGTGATGGAG-3′
(forward) and 5′-TAGCCAAGGGGGTGAGGAAC-3′ (reverse);
+0.17 kb (+177 ∼+353 bp), 5′-TCATTGACGAGGTGAGAAGGAC-3′
(forward) and 5′-GCAGTGTGTTAAAGACCGAGGAG-3′ (reverse);
+2.8 kb (+2841 ∼+2984 bp), 5′-GCTGCCGTGTCTGGTTTATTTG-3′
(forward) and 5′-GCCAAGATTGCCATCTGTGAAG-3′ (reverse).
DNA microarray
Speciﬁc genes (include hINO80, Arp5, Arp8, Ies2 and Ies6) knocked
down with siRNAs in HeLa cells and the total RNA sent to EMTD
Science and Technology Development Co., Ltd. (Beijing, China) for
DNA microarray analysis. The Illumina microarray datasets were
accessible from the National Center for Biotechnology Information
Gene Expression Omnibus (GEO) data repository (http://www.ncbi.
nlm.nih.gov/geo/) using the series accession number GSE68655.
The online biological classiﬁcation tool DAVID (Database for Anno-
tation, Visualization and Integrated Discovery) was used to perform
the enrichment analysis (Huang da et al. 2009; Huang da et al.
2009), Gene Ontology (GO) (Ashburner et al. 2000) function anal-
ysis and Kyoto Encyclopedia of Genes and Genomes (KEGG)
(Ogata et al. 1999) pathway enrichment analysis of differentially
expressed genes (DEGs). During the analysis, P < 0.05 and
FDR < 0.02 genes used in the annotation were deﬁned as statisti-
cally signiﬁcant.
Statistics
Two-tailed student’s t-test was used in this study. Data shown is
mean + SD from at least three independent experiments. Statistical
probability is expressed as *P < 0.05, **P < 0.01.
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